Step 1 topics → Hematology and Oncology → Waldenström Macroglobulinemia

Waldenström Macroglobulinemia

USMLE Step 1 trap: Confuses Waldenström cell of origin with the plasma cell of multiple myeloma. Waldenström arises from a lymphoplasmacytic cell (intermediate between B cell and plasma cell), producing monoclonal IgM.

Waldenström macroglobulinemia (WM) is a low-grade B-cell lymphoma where lymphoplasmacytic cells — sitting developmentally between mature B cells and plasma cells — proliferate in the bone marrow and produce monoclonal IgM. USMLE Step 1 tests this primarily through recognition, and the key misconception is conflating WM with multiple myeloma. They are not the same: WM produces IgM exclusively (not IgG), comes from lymphoplasmacytic cells (not terminally differentiated plasma cells), causes hyperviscosity syndrome (not lytic bone lesions), and does not meet CRAB criteria. That pentameric IgM stays in the vasculature and drives blurred vision, Raynaud's, and neurological symptoms — a clinical picture distinct from myeloma in every dimension.

The exam also uses WM to test mechanism-based reasoning. Why does IgM cause hyperviscosity more than IgG? Because it's a pentamer that stays intravascular. Why no bone lesions? Because the lymphoplasmacytic cell doesn't drive osteoclast activation the way myeloma plasma cells do. These aren't random facts — they're mechanistic consequences of the cell biology, and Step 1 rewards students who understand the 'why' rather than those who memorize isolated bullet points.

The biggest trap is conflating WM with multiple myeloma. Both are plasma cell dyscrasias in the broad sense, both produce a monoclonal protein, and both can cause peripheral neuropathy and fatigue — so students blur them together. But the distinctions are clean and testable: WM = IgM, lymphoplasmacytic cell, hyperviscosity, no CRAB; myeloma = IgG (usually), plasma cell, lytic lesions, hypercalcemia. USMLE Step 1 loves questions that present a patient with 'thick blood' symptoms and force you to distinguish WM from myeloma by identifying these features.

From real student decks
51%have cards covering this topic
32%have mature cards

Common misconceptions

Common mistake
Wrong: Waldenström macroglobulinemia arises from a fully differentiated plasma cell identical to myeloma.
Right: Waldenström arises from a lymphoplasmacytic cell (intermediate between B cell and plasma cell), producing monoclonal IgM.
Multiple myeloma arises from terminally differentiated plasma cells that have lost surface immunoglobulin and B-cell markers. Waldenström's cell of origin — the lymphoplasmacytic cell — is a hybrid: it retains some B-cell surface markers (like CD19, CD20) while also secreting immunoglobulin. This matters clinically because it explains why rituximab (anti-CD20) works in WM but not myeloma, and it's why WM is classified as a lymphoma rather than a myeloma.
Common mistake
Wrong: Waldenström produces IgG just like the most common form of myeloma.
Right: Waldenström exclusively produces monoclonal IgM, which is the largest immunoglobulin and the primary driver of hyperviscosity.
WM exclusively produces IgM — this is not variable like in myeloma. IgM is a pentamer, five times larger than a single IgG molecule, and because of its size it stays predominantly in the bloodstream rather than distributing into tissues. This intravascular concentration is exactly why IgM causes hyperviscosity at much lower concentrations than IgG would. Any question describing a monoclonal protein with hyperviscosity should immediately trigger 'IgM → Waldenström.'
Common mistake
Wrong: Waldenström causes lytic bone lesions and hypercalcemia just like multiple myeloma.
Right: Waldenström does not cause lytic bone lesions or significant hypercalcemia; its hallmark complications are hyperviscosity, peripheral neuropathy, and cryoglobulinemia.
CRAB (hyperCalcemia, Renal failure, Anemia, Bone lesions) is myeloma's signature — it results from plasma cell-driven osteoclast activation and calcium dysregulation. Lymphoplasmacytic cells in WM do not activate osteoclasts, so lytic lesions don't form and calcium stays normal. WM's complications are instead hyperviscosity, type I or II cryoglobulinemia, and peripheral neuropathy (often from IgM binding myelin-associated glycoprotein). Applying CRAB to WM is one of the most common mistakes on this topic.
Common mistake
Gap: Missing that plasmapheresis is first-line acute management for Waldenström hyperviscosity syndrome
Plasmapheresis is the acute treatment of choice for symptomatic hyperviscosity in Waldenström because it rapidly removes circulating IgM.
When a WM patient has symptomatic hyperviscosity, the priority is mechanically removing the IgM from circulation before it causes stroke, blindness, or hemorrhage. Plasmapheresis does exactly this — it filters out the large pentameric IgM rapidly. Chemotherapy and rituximab work long-term by reducing IgM production, but they take weeks to work. Think of plasmapheresis as the bridge: stabilize the patient acutely, then start definitive therapy to prevent recurrence.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know that Waldenström macroglobulinemia arises from lymphoplasmacytic cells — an intermediate between B cells and fully differentiated plasma cells — not from terminally differentiated plasma cells like in multiple myeloma.
  2. Know that WM exclusively produces monoclonal IgM (not IgG), and understand why IgM's pentameric structure and intravascular distribution make it the primary driver of hyperviscosity syndrome.
  3. Recognize the clinical features of hyperviscosity syndrome (blurred vision, epistaxis, headache, Raynaud's phenomenon, neurological symptoms) and know that WM does NOT cause lytic bone lesions or hypercalcemia — the CRAB criteria do not apply.
  4. Know that plasmapheresis is the acute treatment for symptomatic hyperviscosity in WM because it rapidly removes circulating IgM, and that long-term management includes rituximab-based regimens and BTK inhibitors like ibrutinib.

Can you avoid these mistakes?

A 68-year-old man presents with blurred vision, nosebleeds, and a serum protein electrophoresis showing a monoclonal IgM spike. Bone survey is normal. What is the diagnosis, what cell type is responsible, and what is the first step in acute management?
A classmate says 'Waldenström is basically myeloma with IgM instead of IgG.' What are three specific reasons this is wrong?
Why does IgM cause hyperviscosity more readily than IgG, even at similar concentrations? What structural feature of IgM explains this?
A patient with known Waldenström macroglobulinemia develops sudden-onset visual changes and is found to have serum viscosity of 6 cP (normal <1.8). What is the immediate treatment and why is starting rituximab alone insufficient at this moment?

Related topics

Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →